Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data BIOCRYST PHARMACEUTICALS INC files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
26.4
25.2
20.7
48.8
17.8
157
271
331
451
875
Cost of revenue
2.3
1.14
3.73
1.55
7.23
6.41
4.48
12.3
19.1
Gross profit
24.1
24
45.1
16.3
150
264
327
438
856
Research and development
61
67
84.9
107
123
209
253
217
175
166
Selling, general and administrative
11.3
13.9
29.5
37.1
67.9
119
159
214
266
349
Operating income
-48.6
-57.4
-94.2
-99.5
-175
-178
-148
-104
-2.54
341
Interest expense
6.49
8.57
9.18
11.9
14.5
59.3
99.1
108
98.5
78.9
Other non-operating income
-95.9
-123
-84.4
-73.6
Pre-tax income
-109
-183
-182
-244
-226
-87
267
Income tax
0
0
0
0
0
2.25
2.73
0.31
1.93
3.53
Net income
-55.1
-65.8
-101
-109
-183
-184
-247
-227
-88.9
264
EBITDA
-48.1
-56.7
-93.5
-98.7
-174
-177
-147
-102
-1.3
342
EPS, basic
-0.75
-0.78
-0.98
-0.94
-1.09
-1.03
-1.33
-1.18
-0.43
1.26
EPS, diluted
-0.75
-0.78
-0.98
-0.94
-1.09
-1.03
-1.33
-1.18
-0.43
1.21
Shares, basic (weighted)
167
179
186
192
207
210
Shares, diluted (weighted)
73.7
84.5
103
115,600
167
179
186
192
207
219
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
22.1
50.3
26.7
114
272
504
305
111
105
89.7
Short-term investments
32.5
64.1
77.7
22.1
28.2
3.21
120
278
216
185
Receivables
8.77
6.12
4.29
22.1
8.65
29.4
50.6
57
79.1
107
Inventory
0.5
1.65
0
7.04
15.8
27.5
28.7
8.09
5.4
Other current assets
1.44
1.38
2.4
4.42
5.53
9.99
12.6
19.5
13.8
17.2
Total current assets
67
125
114
164
324
566
517
496
422
404
Property, plant and equipment
9.92
9.55
9.14
7.35
7.11
8.71
8.62
7.91
7.78
8.78
Lease right-of-use assets
6.47
4.24
8.68
8.06
7.55
Long-term investments
8.93
41.3
22.4
0
6.83
18.1
0
20.3
61.2
Other non-current assets
3.81
2.03
0.98
3.59
3.8
6.47
6.81
0.08
5.16
5.67
Total assets
89.8
178
147
175
335
588
550
517
490
514
Accounts payable
4.27
6.34
7.77
14
18.7
27.8
14.4
20.9
11.6
15.8
Accrued liabilities
10.8
12.7
15.9
21.4
33.9
72.7
87.6
103
113
126
Deferred revenue
2.02
8.48
0.22
2.12
0.15
1.42
1.22
0
0
Total current liabilities
54.4
74.8
69.5
92.3
106
104
106
150
160
196
Long-term debt
0
120
136
232
303
315
0
Lease liabilities
3.87
5.96
4.03
8.39
7.92
8.57
Other non-current liabilities
2.7
Total liabilities
88.3
94.5
97.6
137
354
695
845
972
966
633
Total debt
23
23
30
50
123
298
232
303
315
0
Paid-in capital
567
715
780
877
1,002
1,098
1,158
1,222
1,291
1,385
Retained earnings
-566
-632
-732
-841
-1,023
-1,208
-1,455
-1,681
-1,770
-1,506
Other comprehensive income
-0.01
-0.24
-0.3
0.04
0
0.18
0.03
1.34
0.92
0.04
Shareholders' equity
1.58
83.8
49.2
38.3
-19.3
-107
-295
-456
-476
-119
Total equity
1.58
83.8
49.2
38.3
-19.3
-107
-295
-456
-476
-119
Total liabilities and equity
89.8
178
147
175
335
588
550
517
490
514
Shares outstanding
73.8
98.4
110
154,082
177
184
188
206
209
213
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-55.1
-65.8
-101
-109
-183
-184
-247
-227
-88.9
264
Depreciation and amortization
0.48
0.7
0.77
0.72
0.75
0.78
1.44
1.66
1.25
1.39
Stock-based compensation
8.49
12.6
9.4
17.7
14.8
34.6
44.7
55.6
65.4
85.1
Deferred income tax
-0.16
0.01
-0.68
-0.35
-1.21
Change in receivables
-2.53
2.65
1.82
-17.9
13.9
-20.8
-21.5
-6.1
-22.7
-36.8
Change in inventory
1.11
0.5
-1.65
1.65
-7.04
-8.77
-12.4
-1.45
-4.16
-1.64
Change in payables
-10.5
3.84
4.49
11.7
17.4
39.4
-22.4
12.5
14.8
57.8
Cash from operations
-53.4
-41.1
-92.6
-89.6
-135
-142
-162
-95.1
-52
347
Capital expenditures
-5.28
-0.33
-0.37
-0.34
-0.51
-2.39
-1.35
-2.17
-1.12
-2.47
Purchases of investments
-14.1
-108
-62.6
-3.02
-49.8
-10
-244
-514
-267
-262
Cash from investing
23.3
-64.6
4.77
77.9
-6.86
15.8
-128
-131
52.6
-13.7
Debt issued
0
73.1
300
0
0
Debt repaid
-240
0
-300
Stock issued
0.32
134
53.4
58.5
93.3
50
0
0
Cash from financing
23.3
136
62.5
99.1
301
360
88
32.5
-5.76
-350
Exchange rate effect
0
0.07
0.57
0.36
-0.94
1.27
Net change in cash
-6.86
29.9
-25.3
87.4
159
233
-201
-194
-6.12
-15
Free cash flow
-58.7
-41.5
-92.9
-89.9
-136
-145
-163
-97.3
-53.1
345
Interest paid
0.9
0
22.1
30.4
23.7
Income taxes paid
0.12
3.54
1.43
1.6
2.8
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $8.59 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
97.8%
Gross profit / revenue.
Operating margin
-33.3%
Operating income / revenue.
EBITDA margin
-33.1%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-40.5%
Pre-tax income / revenue.
Net margin
-40.9%
Net income / revenue.
FCF margin
39.7%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
40.0%
Cash from operations / revenue.
Return on assets (ROA)
-69.0%
Net income / average total assets.
R&D / revenue
21.0%
Research and development expense / revenue.
SG&A / revenue
35.9%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
7.8%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.3%
Capital expenditures / revenue.
D&A / revenue
0.2%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
94.1%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
47.8%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
117.9%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
95.2%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
47.9%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
120.9%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
4.8%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-2.2%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
9.0%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
5.7%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
5.5%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
5.5%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
2.32x
Current assets / current liabilities.
Quick ratio
2.22x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
1.69x
(Cash + short-term investments) / current liabilities.
Debt / assets
70.9%
Total debt / total assets.
Liabilities / assets
181.4%
Total liabilities / total assets.
Net debt
$42.8M
Total debt - cash - short-term investments. Negative means more cash than debt.
Days inventory + days sales outstanding - days payables.
Capex / operating cash flow
0.7%
Capital expenditures / cash from operations, when that is positive.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$1.45
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$3.55
Revenue / diluted weighted shares.
FCF per share
$1.41
Free cash flow / diluted weighted shares.
Operating cash flow per share
$1.42
Cash from operations / diluted weighted shares.
Book value per share
-$1.78
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
2.33x
Market cap / revenue.
P/FCF
5.88x
Market cap / free cash flow. Only when free cash flow is positive.
P/OCF
5.84x
Market cap / cash from operations, when positive.
EV/Sales
2.38x
Enterprise value / revenue.
EV/FCF
5.99x
Enterprise value / free cash flow, when both are positive.
FCF yield
17.0%
Free cash flow / market cap.
Earnings yield
-17.5%
Net income / market cap (the inverse of P/E).
What was BIOCRYST PHARMACEUTICALS INC's revenue in fiscal 2025?
BIOCRYST PHARMACEUTICALS INC reported revenue of $874.8M for fiscal 2025, 94.1% higher than the year before.
Was BIOCRYST PHARMACEUTICALS INC profitable in fiscal 2025?
Yes. Net income was $263.9M, a net margin of 30.2%.
How much free cash flow did BIOCRYST PHARMACEUTICALS INC generate in fiscal 2025?
Cash from operations of $347.4M minus capital expenditures of $2.5M left free cash flow of $344.9M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.